Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
Research News
Donate Now
Parkinson's Research

Research News

Read the latest developments, reporting and analysis from the world of Parkinson's research, including progress made in studies, tools and collaborations funded by The Michael J. Fox Foundation.
  • Study Reveals Risk Factors for Early Psychosis in Parkinson's

    Study Reveals Risk Factors for Early Psychosis in Parkinson's

    A recent study using data from PPMI has identified risk factors that may predict the development of early psychosis in Parkinson's.
    Learn more
  • MJFF Study Making Strides Toward Parkinson's Biomarker

    MJFF Study Making Strides Toward Parkinson's Biomarker

    Researchers haven't yet determined the optimal location or method to sample alpha-synuclein. Learn how MJFF's Systemic Synuclein Sampling Study is hoping to change this.
    Learn more
  • Speeding up to Slow Parkinson’s Down: New Study Shows Exercise Delays PD Progression

    Speeding up to Slow Parkinson’s Down: New Study Shows Exercise Delays PD Progression

    A recent study showed that exercising just 2.5 hours per week could help delay decline in mobility and quality of life.
    Learn more
  • FDA Approves Xadago for Parkinson's Disease

    FDA Approves Xadago for Parkinson's Disease

    The U.S. Food and Drug Administration (FDA) has approved a new drug called Xadago (safinamide) from Newron Pharmaceuticals for people with Parkinson's disease (PD) who are taking levodopa.
    Learn more
  • New Information on the Parkinson's-Gut Connection

    New Information on the Parkinson's-Gut Connection

    A recently published study has revealed differences in gut bacteria in those with Parkinson's disease based on their medications and geographic locations, adding to our growing knowledge.
    Learn more
  • Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies

    Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies

    MJFF CEO Todd Sherer, PhD, discusses varied work happening around c-Abl inhibitors, an emerging therapeutic target that has shown early promise as a potential disease-modifying therapy.
    Learn more
  • Could MAO-B Inhibitors Slow Parkinson's Disease Progression?

    Could MAO-B Inhibitors Slow Parkinson's Disease Progression?

    A new study proposes that MAO-B inhibitors -- drugs used to treat Parkinson's motor symptoms -- may slow disease progression when taken for longer periods of time.
    Learn more
Close-up portrait

Join the Study that's Changing Everything

The Parkinson's Progression Markers Initiative is changing how patients, families, doctors and scientists think about brain disease. Now it needs you.

Get Started
Michael J. Fox in blue sweater posing for the camera.

Patients First

Our Foundation exists for one reason: to speed breakthroughs patients can feel in their everyday lives.

Read Our Promise
"The question most frequently asked of us is: 'How close are we to a cure for Parkinson’s disease?' With over $800 million in Parkinson's research funded to date, the simplest answer is: closer than ever."
Todd Sherer, PhD
Todd Sherer, PhD Chief Mission Officer
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.